Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,784,887
  • Shares Outstanding, K 100,557
  • Annual Sales, $ 63,520 K
  • Annual Income, $ -376,740 K
  • EBIT $ -431 M
  • EBITDA $ -432 M
  • 60-Month Beta 2.35
  • Price/Sales 27.95
  • Price/Cash Flow N/A
  • Price/Book 1.60

Options Overview Details

View History
  • Implied Volatility 63.65% ( -6.50%)
  • Historical Volatility 96.15%
  • IV Percentile 14%
  • IV Rank 33.73%
  • IV High 119.34% on 05/06/25
  • IV Low 35.30% on 05/31/24
  • Put/Call Vol Ratio 0.11
  • Today's Volume 583
  • Volume Avg (30-Day) 1,467
  • Put/Call OI Ratio 2.44
  • Today's Open Interest 30,599
  • Open Int (30-Day) 30,930

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.04
  • Number of Estimates 6
  • High Estimate -0.78
  • Low Estimate -1.28
  • Prior Year -1.11
  • Growth Rate Est. (year over year) +6.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.51 +14.44%
on 05/07/25
20.90 -15.07%
on 05/02/25
+0.75 (+4.41%)
since 04/17/25
3-Month
13.52 +31.24%
on 04/07/25
33.91 -47.66%
on 02/21/25
-15.39 (-46.44%)
since 02/20/25
52-Week
13.52 +31.24%
on 04/07/25
35.25 -49.65%
on 02/18/25
-7.09 (-28.54%)
since 05/20/24

Most Recent Stories

More News
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

BEAM : 17.75 (+0.54%)
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

BEAM : 17.75 (+0.54%)
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

BEAM : 17.75 (+0.54%)
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

Iovance Biotherapeutics, Inc. IOVA incurred a first-quarter 2025 loss of 36 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. In the year-ago quarter, the company reported...

BEAM : 17.75 (+0.54%)
IOVA : 1.9100 (+4.37%)
ELEV : 0.3281 (-3.50%)
ADPT : 9.36 (+1.74%)
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

Amarin Corporation AMRN reported a loss of 4 cents per share for the first quarter of 2025, which was significantly narrower than the Zacks Consensus Estimate of a loss of $1.12. The company had reported...

BEAM : 17.75 (+0.54%)
AMRN : 11.11 (+1.93%)
ANIP : 60.64 (+0.80%)
NTLA : 9.67 (+6.73%)
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates

Beam Therapeutics BEAM reported a loss of $1.24 per share for the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of $1.11. The company had reported a loss of $1.21 per...

BEAM : 17.75 (+0.54%)
IMCR : 32.39 (+4.48%)
ANIP : 60.64 (+0.80%)
NTLA : 9.67 (+6.73%)
Why Beam Therapeutics Stock Tanked on Tuesday

Precision gene-editing company Beam Therapeutics (NASDAQ: BEAM) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced...

BEAM : 17.75 (+0.54%)
NFLX : 1,192.02 (+0.03%)
NVDA : 134.38 (-0.88%)
$SPX : 5,940.46 (-0.39%)
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

BEAM : 17.75 (+0.54%)
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates

Alkermes plc ALKS reported earnings from continuing operations of 13 cents per share for first-quarter 2025, which missed the Zacks Consensus Estimate of 28 cents. The company had reported earnings of...

BEAM : 17.75 (+0.54%)
IMCR : 32.39 (+4.48%)
ADMA : 20.44 (+1.24%)
ALKS : 31.67 (+0.70%)
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

Agios Pharmaceuticals AGIO incurred a loss of $1.55 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.80. In the year-ago quarter, the company had reported...

BEAM : 17.75 (+0.54%)
IMCR : 32.39 (+4.48%)
AGIO : 30.17 (+1.11%)
ADMA : 20.44 (+1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 19.34
2nd Resistance Point 18.82
1st Resistance Point 18.29
Last Price 17.75
1st Support Level 17.24
2nd Support Level 16.72
3rd Support Level 16.19

See More

52-Week High 35.25
Fibonacci 61.8% 26.95
Fibonacci 50% 24.39
Fibonacci 38.2% 21.82
Last Price 17.75
52-Week Low 13.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »